Publications 

---

• Endocr Pract. 2014 May;20(5):463-89. doi: 10.4158/EP14145.PS.
  Consensus statement bythe american association of clinical endocrinologists/american college of endocrinology insulin pump management task force. Grunberger G1, Abelseth JM2, Bailey TS3, Bode BW4, Handelsman Y5, Hellman R6, Jovanovič L7, Lane WS8, Raskin P9, Tamborlane WV10, Rothermel C11.

• Diabetes Obes Metab. 2014 Sep;16(9):827-32. doi: 10.1111/dom.12286. Epub 2014 Mar 25.
  The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Lane W1, Weinrib S, Rappaport J, Hale C.


• Endocr Pract. 2013 Mar-Apr;19(2):196-201. doi: 10.4158/EP12226.OR.
  The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes. Lane WS1, Weinrib SL, Rappaport JM, Hale CB, Farmer LK, Lane RS.

 

• Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.
  The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Lane W1, Weinrib S, Rappaport J.

 

• Endocr Pract. 2010 Sep-Oct;16(5):778-84. doi: 10.4158/EP10014.OR. 

            A prospective trial of U500 insulin delivered by Omnipod in              patients with type 2 diabetes mellitus and severe insulin                  resistance. Lane WS1, Weinrib SL, Rappaport                                      JM, Przestrzelski T.

• N Engl J Med. 2010 Jul 22;363(4):311-20. doi: 10.1056/NEJMoa1002853. Epub 2010 Jun 29. 

            Effectiveness of sensor-augmented insulin-pump therapy                in type 1 diabetes. Bergenstal RM1, Tamborlane                                  WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce                                C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood                              MA; STAR 3 Study Group.​
​

• Endocr Pract. 2009 Jan-Feb;15(1):71-9. 

            High-dose insulin therapy: is it time for U-500 insulin? Lane              WS1, Cochran EK, Jackson JA, Scism-Bacon JL, Corey                            IB, Hirsch IB, Skyler JS.

• Endocr Pract. 2012 Mar-Apr;18(2):170-8. doi: 10.4158/EP11144.OR. 

            Successful management of differentiated thyroid cancer in              a community-based endocrine practice. Weinrib SL1, Lane              WS, Rappaport JM.

• Endocr Pract. 2006 May-Jun;12(3):251-6.

            Use of U-500 regular insulin by continuous subcutaneous                insulin infusion in patients with type 2 diabetes and severe              insulin resistance. Lane WS1.

• Diabetes Care. 2005 Mar;28(3):533-8. 

            Continuous subcutaneous insulin infusion (CSII) of insulin                aspart versus multiple daily injection of insulin                                    aspart/insulin glargine in type 1 diabetic patients                                previously treated with CSII. Hirsch IB1, Bode BW, Garg                      S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski                    JW; Insulin Aspart CSII/MDI Comparison Study Group.

• Mayo Clin Proc. 2004 Dec;79(12):1521-6. 

            Use of the Continuous Glucose Monitoring System to guide              therapy in patients with insulin-treated diabetes: a                              randomized controlled trial. Tanenberg R1, Bode B, Lane                  W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross                          T, Mastrototaro J.

​